Conference
Abstract A185: Phase I clinical, pharmacokinetic, and pharmacodynamic study of SB939, an oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors
Abstract
Abstract
Background: SB939 is an orally available, potent, competitive HDACi selective for Class I, II and IV histone deacetylases. Preclinical evaluation of SB939 in a broad spectrum of xenograft mouse models revealed dose-dependent tumor growth inhibition. In the HCT116 colorectal cancer model, SB939 showed superior activity compared to other HDACi and prolonged histone H3 acetylation (acH3) in tumor tissues lasting ≥ 24 …
Authors
Siu LL; Hotte SJ; Chen EX; Hirte HW; Powers J; Stayner L-A; Iacobucci A; Novotny-Diermayr V; Zhu J; Eisenhauer EA
Volume
8
Pagination
pp. a185-a185
Publisher
American Association for Cancer Research (AACR)
Publication Date
December 10, 2009
DOI
10.1158/1535-7163.targ-09-a185
Conference proceedings
Molecular Cancer Therapeutics
Issue
12_Supplement
ISSN
1535-7163